NANOV.OL Live signals | Maximize Profits with Getagraph.com

BUY 444472 min ago

@ Kr.1.932

Issued: 5 Jul 2023 @ 10:25

Return: 0.00%

Live Chart Being Loaded With Signals

Commentary (5 Jul 2023 @ 10:25):

Stats
Today's Volume	2.50M
Average Volume	3.95M
Market Cap	451.20M
EPS	Kr.0 ( 2024-02-26 )
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	-0.826
ATR14	Kr.0.389 (20.16%)

Volume Correlation

Long: 0.78 (moderate)

Short: 0.62 (weak)

Signal:(50.96) Neutral

Nordic Nanovector ASA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nordic Nanovector ASA Correlation - Currency/Commodity

0.77
( moderate )

0.56
( weak )

-0.14
( neutral )

0.23
( neutral )

0.51
( weak )

-0.69
( moderate negative )

Financial Reports:

No articles found.

Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company\'s lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.